Opinion
Video
Introduction and Current Landscape of HER2 in NSCLC
Key Takeaways
- HER2 mutations involve genetic alterations, while HER2 expression refers to protein overexpression, both impacting NSCLC treatment strategies.
- Fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine are key HER2-directed therapies recommended by NCCN guidelines for HER2-positive NSCLC.
Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy and safety of current treatments like trastuzumab deruxtecan and ado-trastuzumab emtansine, and considering their potential to reshape treatment approaches as recommended in NCCN guidelines.
Video content above is prompted by the following:
- Evaluate the efficacy and safety profiles of current and emerging HER2-directed therapies in NSCLC, and their potential impact on treatment paradigms.
- (Bazhenova) Describe the difference between HER2 mutation and HER2 expression.
- (Kim) Provide an overview of the current HER2-directed therapies (fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine) available and how they’re recommended in the NCCN guidelines.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
